- Home
- PCRX vs XPEL Comparison
PCRX vs XPEL Comparison
Compare PCRX & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- XPEL
- Stock Information
- Founded
- PCRX 2006
- XPEL 1999
- Country
- PCRX United States
- XPEL United States
- Employees
- PCRX N/A
- XPEL N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- PCRX Health Care
- XPEL Industrials
- Exchange
- PCRX Nasdaq
- XPEL Nasdaq
- Market Cap
- PCRX 1.2B
- XPEL 984.3M
- IPO Year
- PCRX 2011
- XPEL N/A
- Fundamental
- Price
- PCRX $26.86
- XPEL $34.32
- Analyst Decision
- PCRX Buy
- XPEL
- Analyst Count
- PCRX 6
- XPEL 0
- Target Price
- PCRX $30.00
- XPEL N/A
- AVG Volume (30 Days)
- PCRX 592.7K
- XPEL 157.4K
- Earning Date
- PCRX 11-05-2025
- XPEL 11-06-2025
- Dividend Yield
- PCRX N/A
- XPEL N/A
- EPS Growth
- PCRX N/A
- XPEL 2.75
- EPS
- PCRX N/A
- XPEL 1.76
- Revenue
- PCRX $705,848,000.00
- XPEL $448,897,000.00
- Revenue This Year
- PCRX $7.36
- XPEL $12.54
- Revenue Next Year
- PCRX $10.07
- XPEL $10.52
- P/E Ratio
- PCRX N/A
- XPEL $19.53
- Revenue Growth
- PCRX 2.25
- XPEL 9.96
- 52 Week Low
- PCRX $13.04
- XPEL $24.25
- 52 Week High
- PCRX $27.64
- XPEL $47.23
- Technical
- Relative Strength Index (RSI)
- PCRX 61.04
- XPEL 41.63
- Support Level
- PCRX $25.63
- XPEL $35.69
- Resistance Level
- PCRX $27.11
- XPEL $37.76
- Average True Range (ATR)
- PCRX 0.96
- XPEL 1.52
- MACD
- PCRX -0.05
- XPEL -0.35
- Stochastic Oscillator
- PCRX 68.80
- XPEL 1.81
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.